Feature | Left Atrial Appendage (LAA) Occluders | May 18, 2018

Device-related Thrombus After Watchman LAA Closure Occurs in Small Number of Patients

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman LAA Occluder device in an echo image. #HRS2018

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman device in an echo image.

May 18, 2018 — Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism from the LAA, but a new study shows that thrombus forms on the face of the device in about 3.7 percent of patients and it can embolize. The study was presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

While not frequent, when present, thrombus on the face of an LAA occluder is associated with a high rate of ischemic stroke, said study presenter Vivek Y. Reddy, M.D., from the Icahn School of Medicine at Mount Sinai, New York. To better understand the mechanism of stroke after LAAC, he said the study looked at the incidence, predictors and clinical outcomes of device-related thrombus (DRT).

Researchers studied the device arms of four prospective FDA trials: PROTECT-AF n=463; PREVAIL n=269; CAP n=566; and CAP2 n=579. Surveillance transesophageal echos (TEE) were required at 45 days and 12 months. Researchers assessed both the incidence of DRT during these TEEs (plus other unscheduled TEEs) and clinical outcomes, both post-procedure stroke or systemic embolization. 

Of the cohort with successful implantation (1,739 patients; 7,159 patient-years FU; CHADS-VASc = 4.0), DRT was four Heart Rhythm 2018 seen in 65 pts (3.74%). The annual rates of systemic embolization without and with DRT were 1.78% and 7.46% (RR 3.55, 95% CI 2.18 – 5.79; p < 0.0001), ischemic systemic embolization rates were 1.65% and 6.28% (RR 3.22, 95% CI 1.90 - 5.45; p < 0.0001; Fig 1). On multivariate logistic regression analysis, DRT was predicted by: permanent AF – OR 2.5, p=0.0004; LVEF – OR 0.97 p=0.02; CHADS-VASc score – OR 1.25, p=0.0075; LAA diameter – OR 1.05, p=0.046). DRT and systemic embolization both occurred in 17 of 65 patients (26.2%); temporal analysis suggests a causal relationship between DRT and systemic embolization in 12 of 17 patients (70%; Fig 2). Conversely, after LAAC, most systemic embolization (123 of 142, 87%) occurred in patients without DRT.

Reddy said future efforts should be made to minimize DRT to further improve the efficacy of LAAC.

 

Related LAA Watchman Occluder Content:

VIDEO: New Data on LAA Occlusion From the PREVAIL and PROTECT Trials — interview with Vivek Reddy, M.D.

Mixed Results in PREVAIL Trial Comparing Five-Year Data for LAA Closure Compared to Warfarin at TCT 2017

Occluding the Left Atrial Appendage (LAA)

VIDEO: Post-FDA Approval Experience of LAA Occluders — interview with David Holmes, M.D.

Four-Year Data Shows Watchman Device Superior to Warfarin in Afib patients

 

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

#HRS2018 #HRS18

Related Content

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual...
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart at
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce